<DOC>
	<DOCNO>NCT00297167</DOCNO>
	<brief_summary>The primary efficacy objective study compare coefficient fat absorption ( CFA ) follow oral administration Aptalis Pharma 's ( formerly Eurand Pharmaceuticals ) pancreatic enzyme product ( PEP ) capsule placebo participant cystic fibrosis ( CF ) exocrine pancreatic insufficiency ( EPI ) .</brief_summary>
	<brief_title>Study Evaluate Safety Efficacy EUR-1008 ( APT-1008 ) Pancreatic Enzyme Product Participants With Cystic Fibrosis Exocrine Pancreatic Insufficiency</brief_title>
	<detailed_description>This randomize , double-blind , placebo-controlled , 2-treatment , crossover , multicenter trial participant CF EPI . The study consist screen period ( 1 14 day ) , washout period ( 2 day ) , dose titration/stabilization period ( 6 9 day ) , blind randomized treatment period ( 6 7 day ) , open-label normalization period 1 ( 5 14 day ) , blind crossover treatment period ( 6 7 day ) , follow open-label normalization period 2 ( 7 day ) . The order treatment ( placebo follow EUR-1008 [ APT-1008 ] EUR-1008 [ APT-1008 ] follow placebo ) determine randomization begin randomization treatment period carry crossover treatment period . The start dose 1,000 lipase unit per kilogram per meal ( lipase units/kg/meal ) , titrate control symptom EPI , total dose exceed 10,000 lipase units/kg/day .</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<mesh_term>Exocrine Pancreatic Insufficiency</mesh_term>
	<criteria>Participants age great equal ( &gt; = ) 7 year time enrollment Participants weight 70 kg less adequate nutritional status indicate body mass index ( BMI ) &gt; =20 kg/m^2 age 18 , BMI twenty fifth percentile participant age 7 17 year Participants confirm diagnosis CF 2 clinical feature consistent CF , either genotype 2 identifiable mutation consistent CF sweat chloride concentration 60 milliequivalent per liter quantitative pilocarpine iontophoresis Participants confirm diagnosis EPI currently receive treatment commercially available PEP document fecal elastase &lt; 100 microgram per gram stool ( documentation available , stool sample take Screening determination fecal elastase ) . Clinically stable participant evidence acute respiratory disease acute condition Participants willing able interrupt current CF treatment CFrelated malabsorption along medication may affect gastric motility stomach power hydrogen ( pH ) Participants 18 year age old ) understand requirement study , b ) provide write informed consent , c ) agree abide study restriction , ) return require assessment Participants 7 17 year age must parent ( ) legal guardian provide write informed consent , agree abide study restriction Females participant childbearing potential must negative serum pregnancy test screening must agree use adequate birth control study Participants fibrosing colonopathy , hyperuricemia hyperuricosuria Participants allergic pork porcine PEPs Participants force expiratory volume ( FEV1 ) &lt; 30 percent predict FEV1 screen Participants acute systemic administration antibiotic reason previous 4 week ; however , low stable dose antibiotic chronic treatment inhalatory antibiotic allow Participants hepatic insufficiency define history presence ascites serum albumin level &lt; 3.0 milligram/deciliter , coagulopathy international normalize ratio great 1.7 Participants use acute dose steroid previous 2 week ; however , low chronic dos steroid allow Participants history current diagnosis distal ileal obstruction syndrome ( DIOS ) evidence suggested constipation , abdominal pain , anorexia , early satiety , recurrent vomiting , palpable fecal mass physical examination ( absence DIOS confirm Xray abdomen take screen ) Participants solid organ transplant surgery affect bowel . Participants history appendectomy inguinal ( nonincarcerated ) hernioplasty meconium ileus without need bowel resection could enrol . Gastrointestinaltubefed patient , absence dump syndrome , also eligible Participants history current screening evaluation hyperglycemia define 8hour fast blood glucose ( FBG ) &gt; 126 mg/dL , CFrelated diabetes determine accord Cystic Fibrosis Foundation ( CFF ) Consensus Conference January 1999 ( Section IX Part II ) , : ) FBG &gt; 126 mg/dL ( 7.0 millimoles per liter [ mmol/L ] ) two occasion b ) FBG &gt; 126 mg/dL ( 7.0 mmol/L ) plus casual ( without regard time day last meal consume ) glucose level &gt; 200 mg/dL ( 11.1 mmol/L ) c ) Casual ( previously call random ) glucose level &gt; 200 mg/dL ( 11.1 mmol/L ) two occasion symptom Participants use enzyme preparation excess 10,000lipase units/kg/day Participants use immunosuppressive drug Participants expect inability tolerate washout period and/or placebo treatment Participants participate investigational study drug , biologic , device currently approve marketing , within 30 day screen visit Female participant pregnant breastfeeding , unwilling use effective birth control study Participants condition would , investigator 's opinion , limit participant 's ability complete study</criteria>
	<gender>All</gender>
	<minimum_age>7 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>CF</keyword>
	<keyword>Cystic Fibrosis</keyword>
	<keyword>EPI</keyword>
	<keyword>Exocrine Pancreatic Insufficiency</keyword>
	<keyword>Pancreatic</keyword>
	<keyword>Enzyme</keyword>
	<keyword>PEP</keyword>
</DOC>